In the latest decades, the development of PET/CT radiopharmaceuticals, targeting the Prostate-Specific Membrane Antigen (PSMA), changed the management of PCa patients thanks to its higher diagnostic accuracy compared with conventional imaging both in staging and recurrence [20]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.